





Claire
BIOT

Vice President Life
Sciences & Healthcare
Industry

Dassault Systèmes

EXTERNAL FORCES DRIVING TRANSFORMATION IN LIFE SCIENCES AND HEALTHCARE



# EXTERNAL FORCES DRIVING TRANSFORMATION IN LIFE SCIENCES AND HEALTHCARE

Claire Biot, PhD





# WHAT LIFE SCIENCES COMPANIES VALUE THE MOST



### WHAT LIFE SCIENCES COMPANIES VALUE THE MOST

# Patient Centricity / Caregiver Centricity

"Power Healthier People"

"Foster a Seamless Patient Journey"

"Unburden Healthcare Workers"

### **Innovation & Excellence**

"Do Breakthrough Science"

"Put Tech in MedTech"

"Propose the **Right treatment** at the Right patient at the Right time"

"Deliver Healthcare as a Service"

# **Sustainability**

"Never compromise on Quality, Cybersecurity, Data privacy"

"Protect our Planet"

"No Patient left behind"

# Industry Business Drivers

Addressing the business challenges of Life Sciences & Healthcare Industry



Multifactorial Complex Diseases



Access to Science & Technology Breakthroughs



Patient Autonomy



**Cost Pressure** 



Intense Competition, New Players



Supply Chain Complexity



Regulatory Pressure



Mandate




# Industry Business Drivers

Addressing the business challenges of Life Sciences & Healthcare Industry



Multifactorial Complex Diseases



Access to Science & Technology Breakthroughs



Patient Autonomy



**Cost Pressure** 



Intense Competition, New Players



Supply Chain Complexity



Regulatory Pressure



Sustainability Mandate



# Sustainability Mandate | A zoom on SBTI Initiative






The Science Based Targets initiative (SBTi) was established to help companies to set emission reduction targets in line with climate sciences and the Paris Agreement goals.












SBTi's founding members

Figure [5.2] Overview of GHG Protocol scopes and emissions across the value chain



**Direct** emissions Scope 1

Scope 2

**Indirect** emissions from generation of purchased energy

Scope 3

Indirect emissions from production and transportation of goods and services



Source: World Economic Forum

## **#SBTI: SCIENCE-BASED TARGET INITIATIVE**

Reducing the life sciences industry carbon footprint





282 companies set SBTicompliant actions in 2023 vs 90 companies in 2022



Half of Top 50 BioPharmas and Top 50 Medtechs\* set SBTi compliant actions



Average scope 1 & 2 reduction was 62% in 2023 vs **53%** in 2022



26 companies had a SBTi validated net zero target in 2023



### **ROAD TO NET-ZERO**

### **Core activities**

### **Inhalers**

• Finding greener propellants in metered-dose inhalers





### **Eco-design**

- In drugs: using greener chemicals and minimize hazardous chemicals
- In medical devices: reducing the use of plastics, designing recyclable devices













### Non-core activites



Photovoltaic park construction & renewable energy use







### **Eco-building**

LEED\* and ISO 50001:2018\*\* certified buildings.

Scientific

sanofi

### Reforestation

 Offsetting remaining carbon emission by supporting reforestation GSK U NOVARTIS

# **#GENERATIVE AI**

Transforming the whole Life Sciences industry



Access to Science & **Technology** Breakthroughs



Gen Al represents an annual opportunity of \$15B-\$28B in Research & Early Discovery



Gen AI can lead to -30% writing time in regulatory filings



Gen AI can reduce by 10% procurement management costs



Gen Al can decrease patient drop-offs by 10-15%



# WELCOMING SANOFI ON STAGE!

Can PLM Solutions Accelerate the Launch of New Medicines?

#Immunology

#GenAl #Nanobodies

#Patient Communities

#Margins

#BestInClass
#FirstInClass

#Standardization #Flexibility

#Regulatory Flexibility

#Planet
#AccessTo
Care





# THANK YOU FOR YOUR INTEREST